What is the appropriate workup and management for hematuria in a 59-year-old female?

Workup and Management of Hematuria in a 59-Year-Old Female

A 59-year-old woman with hematuria requires risk stratification using the 2025 AUA/SUFU criteria, followed by appropriate imaging and cystoscopy based on her risk category—this approach prevents both over-evaluation of low-risk patients and under-evaluation of those at meaningful cancer risk.

Initial Clinical Assessment

Begin by confirming true hematuria through proper urinalysis and obtaining specific risk-stratifying information 1:

• Quantify the degree of hematuria: Count RBCs per high-power field on microscopic urinalysis (not just dipstick)
• Detailed smoking history: Calculate pack-years (packs per day × years smoked)
• History of gross hematuria: Even if currently microscopic
• Additional urothelial cancer risk factors: Occupational chemical exposures, pelvic irradiation, chronic UTIs, analgesic abuse, family history of urologic malignancies
• Serum creatinine and blood pressure: To assess for renal parenchymal disease
• Rule out transient causes: Active UTI (perform urine culture), menstruation, recent vigorous exercise, recent urologic procedures 2

Critical pitfall: Do not proceed with full urologic workup if UTI is present—treat infection first and repeat urinalysis. However, if hematuria persists after treatment, full evaluation is mandatory 2.

Risk Stratification (2025 AUA/SUFU Guidelines)

For your 59-year-old female patient, apply the updated 2025 risk stratification system 1:

Low/Negligible Risk (0%-0.4% malignancy risk)

Patient must meet ALL of the following:

• Age <60 years
• 3-10 RBC/HPF
• Never smoker or <10 pack-years
• No additional urothelial cancer risk factors

Intermediate Risk (0.2%-3.1% malignancy risk)

Patient meets ONE OR MORE of:

• Age ≥60 years (this is your patient's category based on age alone)
• 11-25 RBC/HPF
• 10-30 pack-years smoking history
• Any additional urothelial cancer risk factors

High Risk (1.3%-6.3% malignancy risk)

Patient meets ONE OR MORE of:

• 25 RBC/HPF

• 30 pack-years smoking history

• One or more additional risk factors PLUS any high-risk feature

Important update: Women cannot be categorized as high-risk based on age alone in the 2025 guidelines—this represents a significant change from 2020 guidelines, reflecting data showing lower urothelial malignancy risk in women 1.

Imaging Recommendations

For Low-Risk Patients

• Shared decision-making regarding imaging versus repeat urinalysis
• If imaging pursued: Ultrasound of kidneys is appropriate
• Avoid CT urography in this group to prevent unnecessary radiation exposure

For Intermediate-Risk Patients (Your 59-Year-Old Patient)

CT urography (CTU) is the preferred imaging modality 2:

• Includes unenhanced phase, nephrographic phase, and excretory phase (≥5 minutes post-contrast)
• Thin-slice acquisition with multiplanar reconstructions
• Evaluates both upper and lower urinary tracts comprehensively
• Detects stones, masses, and urothelial lesions

Alternative if CT contraindicated: MR urography with contrast-enhanced sequences including excretory phase 2

For High-Risk Patients

• CT urography is mandatory 2
• Consider more aggressive follow-up protocols

Radiation consideration: While CTU involves significant radiation exposure, the cancer detection benefit outweighs radiation risk in intermediate and high-risk patients 2.

Cystoscopy

Cystoscopy should be performed in addition to imaging for intermediate and high-risk patients 2. This evaluates the bladder and urethra for:

• Bladder masses/tumors
• Urethral strictures
• Inflammatory conditions

Cystoscopy is essential because imaging alone may miss flat urothelial lesions like carcinoma in situ.

Special Considerations for Women

• Perform pelvic examination to exclude gynecologic sources (cervical lesions, vaginal pathology) 2
• Consider interstitial cystitis if chronic pelvic pain accompanies hematuria 2
• Anticoagulation therapy does NOT alter the evaluation—proceed with full workup regardless 2

Concurrent Nephrology Evaluation

If any of the following are present, refer to nephrology while continuing urologic evaluation 2:

• Dysmorphic RBCs or RBC casts
• Significant proteinuria
• Elevated creatinine
• Hypertension

These suggest glomerular disease, but this does NOT preclude urologic malignancy evaluation.

Tobacco Cessation

If your patient smokes, provide immediate cessation counseling and facilitate evidence-based treatment 1. This is both therapeutic and preventive.

What NOT to Do

• Do not order voided urine cytology as part of routine evaluation—it lacks sensitivity and does not obviate further workup if negative 3
• Do not delay evaluation in patients on anticoagulation 2
• Do not skip imaging in intermediate/high-risk patients even if cystoscopy is normal
• Do not use simple CT abdomen/pelvis instead of dedicated CT urography—the excretory phase is essential 2

Summary Algorithm for Your 59-Year-Old Female

1. Confirm hematuria on proper urinalysis (≥3 RBC/HPF)
2. Exclude transient causes (UTI, menstruation, trauma)
3. Risk stratify using smoking history, degree of hematuria, and additional risk factors
4. At minimum, she is intermediate-risk based on age ≥60
5. Order CT urography (or MR urography if contraindication)
6. Refer for cystoscopy
7. Check serum creatinine; if elevated with proteinuria/casts, add nephrology referral
8. Provide smoking cessation if applicable

This structured approach balances cancer detection (mortality reduction) against unnecessary procedures in low-risk patients (quality of life), as prioritized by the most recent 2025 AUA/SUFU guidelines 1.